Rallybio Earnings Call Transcripts
Fiscal Year 2026
-
The merger creates a leading TCE therapeutics company for autoimmune diseases, combining robust pipelines and over $500 million in capital to advance multiple candidates into late-stage clinical trials. The combined entity aims for global leadership and accelerated development timelines.
-
Stockholders approved an amendment for a reverse stock split at a ratio between 1:5 and 1:20, with a quorum of 82.81% present. Final results will be disclosed in a Form 8-K within four business days.
Fiscal Year 2025
-
RLYB212 was discontinued due to clinical limitations, shifting focus to RLYB116, a novel C5 inhibitor targeting rare diseases like APS, with adaptive clinical trials and data readouts expected in Q3 and Q4. Preclinical ENPP1 inhibitor data and financial updates are also anticipated soon.
-
Three rare disease programs are advancing, with the FNAIT prevention trial enrolling its first pregnant patient and data expected in 2Q/3Q. The complement Factor V inhibitor and ENPP1 inhibitor are progressing, targeting significant unmet needs and market opportunities.
Fiscal Year 2024
-
Four rare disease programs have advanced significantly, with manufacturing and assay improvements revitalizing the complement C5 inhibitor and new best-in-class engineering for Matriptase-2. The FNAIT program is now in phase 2 with pregnant women, and the oral ENPP1 inhibitor has reached lead optimization.
-
RLYB 116 has undergone manufacturing improvements, eliminating host cell protein impurities and enabling higher, well-tolerated dosing. Clinical and biomarker data support its potential as a best-in-class, patient-friendly C5 inhibitor, with a confirmatory PKPD study set for Q2 2025 and a $6B market opportunity across key indications.